ABEmax mRNA (m1ψ substitution)
ABEmax mRNA encodes the ABEmax (Adenine Base Editor) protein, a second-generation genome-editing tool for precise adenine-to-guanine (A-to-G) conversions in DNA. Delivered as mRNA, it ensures rapid, high transient expression proportional to mRNA quantity without requiring nuclear uptake. Extensively characterized for its targeting window and off-target effects, ABEmax is ideal for research in gene function, genetic diseases, and therapeutic development.
Croyez’s ABEmax mRNA is produced through in vitro transcription, featuring a Cap1-modified 5' end, a poly(A) tail at the 3' end, and modified nucleotides to reduce immune response. These enhancements ensure stability and performance, allowing the mRNA to function like natural mature mRNAs in cells.
.png)
.png)
mRNA Length:
5962 nt
Base Composition:
N1-Me-pUTP (N1-mψ)
Concentration:
1.0 mg/ mL
Cap Modification:
Cap 1 structure
Poly A Tail:
Yes
Form:
Liquid
Buffer:
1 mM sodium citrate buffer, pH 6.4.
Storage:
Products can be stored at -80°C or below.
We recommend to aliquot the mRNA solution for a better storage. Avoid repeated freeze/thaw cycles.
Shipping:
The products are shipped on dry ice and should be avoided for freeze-thaw cycles.
Application:
Gene Function Research, Genetic Disease Studies, Therapeutic Development, Genetic Modification
Shipping Conditions:
Dry ice
5962 nt
Base Composition:
N1-Me-pUTP (N1-mψ)
Concentration:
1.0 mg/ mL
Cap Modification:
Cap 1 structure
Poly A Tail:
Yes
Form:
Liquid
Buffer:
1 mM sodium citrate buffer, pH 6.4.
Storage:
Products can be stored at -80°C or below.
We recommend to aliquot the mRNA solution for a better storage. Avoid repeated freeze/thaw cycles.
Shipping:
The products are shipped on dry ice and should be avoided for freeze-thaw cycles.
Application:
Gene Function Research, Genetic Disease Studies, Therapeutic Development, Genetic Modification
Shipping Conditions:
Dry ice
